Stephane Bancel - 26 Feb 2026 Form 4 Insider Report for Generate Biomedicines, Inc. (GENB)

Role: Director
Signature: /s/ Michael Wolf, Attorney-in-Fact
Issuer symbol: GENB
Transactions as of: 26 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 02 Mar 2026, 17:50:49 UTC
Previous filing: 13 Feb 2026
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bancel Stephane	Director	GENERATE BIOMEDICINES, INC., 101 SOUTH STREET, SUITE 900, SOMERVILLE	/s/ Michael Wolf, Attorney-in-Fact	02 Mar 2026	0001443340

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GENB	Common Stock	Conversion of derivative security		+724,160			724,160	02 Mar 2026	By OCHA LLC	F1, F2
holding	GENB	Common Stock						460,829	26 Feb 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	GENB	Stock Option (Right to Buy)	Award	$0	+29,561		$0.000000	29,561	26 Feb 2026	Common Stock	29,561	$16.00	Direct	F3
transaction	GENB	Series A Preferred Stock	Conversion of derivative security	$0	-1,100,000	-100%	$0.000000	0	02 Mar 2026	Common Stock	724,160		By OCHA LLC	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date.
F2	Shares held by OCHA LLC, of which the Reporting Person is the controlling unit holder and sole managing member. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F3	The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.